Progress has been made in the development and validation of rules that attempt ito predict a low risk (!10%) of severe infection or clinical complications in patients with cancer, fever, and neutropenia. It is uncertain, however, which model is optimal, with respect to test characteristics, applicability, and interinstitutional reliability, and prospective model validation in a multicenter context among outpatients has not been performed. Clinical criteria, such as comorbidities and performance status, remain critical in the risk-assessment process and probably are used by most physicians caring for patients with cancer who are febrile and neutropenic. Clinical prediction rules might be improved in the future by including measurements of inflammatory markers, such as procalcitonin. Reliable prediction of the risk of medical complications may be relevant for decisions regarding parenteral versus oral antimicrobial therapy, but it is definitely needed for decisions regarding site of care. Site-of-care decisions require thorough assessment not only of medical criteria, but also of psychosocial and organizational and/or logistic criteria. If the appropriate infrastructure to provide follow-up is available, home-based therapy with oral (or parenteral) antibiotics is an acceptable option in the care of patients with cancer who have intercurrent febrile neutropenia and a predicted low risk for medical complications.
addition, the early French report remains one of the few studies that have investigated self-administration of antibiotic therapy in a situation that was believed to involve a high risk of adverse outcomes. The landmark randomized, controlled trials conducted by Malik and colleagues from Pakistan in 1992 and 1995 [5, 6] confirmed the efficacy of oral antibiotic therapy given to inpatients and outpatients with febrile neutropenia.
A survey from France indicates that, currently, two-thirds of cancer centers surveyed recommend home-based therapy in patients with fever and a short duration of neutropenia [7] . Of 42 health care-professional respondents from Canada, approximately two-thirds initially would choose outpatient management for pediatric patients with cancer, fever, and neutropenia [8] . A recently conducted, large survey from the United States shows that almost all hematologists and oncologists have experience giving oral outpatient therapy to patients with febrile neutropenia; 28% of the responding physicians indicated having used outpatient therapy for у65% of their patients [9] . Thus, outpatient management appears to be a widely accepted option.
According to recent critical reviews and meta-analyses [4, [10] [11] [12] [13] [14] , oral therapy or early switch to oral therapy are valuable evidence-based options for the management of febrile, neutropenic patients, and it is unlikely that additional studies will Figure 1 . A systematic review and meta-analysis of randomized, controlled studies of oral versus intravenous empirical therapy for fever in patients with cancer and neutropenia [5, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Failure rates by per-protocol analysis are shown. Intention-to-treat analysis yielded similar results. Several of these studies were performed among inpatients only. A/C, amoxicillin/clavulanic acid; A/S, ampicillin/sulbactam; Cipro, ciprofloxacin; Clinda, clindamycin. Adapted from [7, 8] .
alter this body of evidence (figure 1). Also, since the French report appeared in 1991, a fluoroquinolone, such as ciprofloxacin, prescribed together with an agent with better coverage of streptococci, has remained the best studied oral regimen in low-risk patients with cancer and febrile neutropenia, at least among adult patients (figure 1). The definition of "low risk," however, has remained key in the discussion of when and how patients can be treated safely with oral therapy and discharged from the hospital in the presence of fever and neutropenia. What follows is a summary of that discussion that is based on a review of the literature and personal experience. It will be observed that there is a need to have more prospective validations of prediction rules and evaluations of outpatient treatment of low-risk, febrile, neutropenic patients. Only a few of the controlled clinical trials performed so far that are included in the meta-analyses have analyzed outpatient therapy.
LOW RISK OF WHAT: NO RESPONSE TO THERAPY OR COMPLICATIONS
Failure to respond to empirical therapy, defined as defervescence without the need for therapy modification, and the development of serious medical complications obviously are not the same, and factors associated with early-therapy response are not necessarily factors significantly associated with adverse ultimate outcomes that include complications or death [29] . Patients with gram-positive bacteremia, for example, often require therapy modification, and the success of initial therapy appears to be poor when compared with that in patients with gram-negative bacteremia [30] . However, serious medical complications usually are less frequently associated with gram-positive bacteremia than with gram-negative bacteremia [29, 31, 32] . Many cases of gram-positive bacteremic infection are caused by low-virulent, coagulase-negative staphylococci that, because of the high prevalence of oxacillin resistance, often require a change in the initial therapy, yet often have a benign clinical course.
In both the Talcott classification of risk groups [33] and the scoring system proposed by the Multinational Association for Supportive Care in Cancer (MASCC) group [34] , a serious medical complication but not a response to therapy has been the end point for risk prediction. I believe that the introduction of this end point represents major progress in the discussion of risk assessment in the field of febrile neutropenia. Although the definition of a serious medical complication has been somehow arbitrary and the MASCC system encompasses different conditions that may not be considered to be of similar relevance by different panels of experts, this end point appears to be relevant for both hospitalized and ambulatory-care patients; it includes complications that require therapeutic consequences other than changes in antimicrobial drug regimen (table 1) . In outpatients, a low risk for the development of a complication means a low risk for hospitalization. Only second in importance after the site-of-care decision is the assessment of the eligibility to receive oral versus intravenous therapy. Common criteria for the eligibility to receive oral therapy include the absence of contraindications against fluoroquinolone treatment, an expectation of compliance with the oral drug regimen, and an expectation of adequate enteral absorption.
PREDICTION OF A LOW RISK OF COMPLICATIONS: VALIDATED RULES
Unfortunately, the sensitivity of the Talcott classification was rather limited (∼30%), and the misclassification rate was high (table 2). Many patients who did not develop any complication and had an uneventful course were not identified by the prediction rule. When the rule was used on patients discharged for home-based intravenous therapy after 2 days of inpatient observation, the complication rate was higher than expected, and the rehospitalization rate was 30% [35] . This rate appears to be high, compared with rates in other studies of home-based intravenous therapy (in which rehospitalization rates were 0%-25%), but the rate improved obviously in a more recent followup study [36] .
The MASCC group proposed a scoring system based on patient history, age, outpatient status, acute clinical status, and severity of disease [34] . The clinical prediction rule derived from the score identifies as low-risk patients those who have a score 120. This threshold is a compromise between a safe positive predictive value (with a minimal rate of patients being falsely identified as being at low risk) and a misclassification rate that would not be too high. The scoring system is suitable for daily clinical practice because of its simplicity, which includes the relatively broad categorization of general clinical status, termed "burden of illness" (no and/or mild versus moderate versus more severe symptoms) (table 2). By using the score, it should be possible to identify at an early stage, with high sensitivity (∼70%), patients at a risk of !10% for developing serious medical complications (table 3) . This greater sensitivity is an advantage over the Talcott classification.
The expected complication rate of !10% is substantially lower than the risk for serious medical complications among patients not identified by the score as being at low risk (expected complication rate, ∼40%). One has to admit, however, that the rate of !10% includes 1% and 9%, and there has been no real consensus regarding whether this threshold rate of 10% is acceptable. Of note, outpatient treatment of febrile patients with neutropenia selected on the basis of more or less different formal risk prediction algorithms has been associated previously with a (re)hospitalization rate of ∼5% to ∼20% [4] . Besides perhaps having better sensitivity, the MASCC model, if consistently associated with a rate of hospitalization much lower than 10%, could offer advantages with respect to positive predictive value over more conventional, less formal low-risk prediction algorithms.
Unfortunately, the MASCC model has not been validated extensively among outpatients. There are preliminary data [10] regarding a single center's prospective validation of the MASCC score among patients discharged from the hospital early and given oral therapy (table 4). Significant noneligibility for oral fluoroquinolone therapy and for discharge from the hospital for a variety of reasons was observed (often because of a patient's or a physician's reluctance to accept hospital discharge), resulting in a surprisingly low proportion of low-risk patients eventually being discharged from the hospital and given oral therapy. Among those patients, the rehospitalization rate was 4% (2 of 52 patients). In another study from Greece, the hospitalization rate in outpatients identified as being at low risk by the MASCC score was similar (5 [9%] of 55 patients) [37] . Lack of experience with the MASCC score in the international, multicenter context of day care or home care limits its usefulness and its wider application. The current prospective trial among low-risk patients with febrile neutropenia conducted by the European Organization for Research and Treatment of Cancer (EORTC), which includes a MASCC score of 120 among its inclusion criteria, will provide more information about the usefulness and performance of the score in an international context. The dynamic aspects in the risk prediction process (e.g., how much time is needed to assess the "burden of illness" required in the MASCC score) and in the development of complications so far have not been addressed adequately. Do current risk prediction models, such as the MASCC score, remain appropriate, discriminatory over time, and relevant as new clinical and laboratory information becomes available? Determining reliable risk assessment at initial presentation is more difficult than is predicting risk after clinical observation for 24 or 48 h, using additional critical information that is initially not available. Do we still need the MASCC score at this later point in time during febrile neutropenia, or is expert clinical judgement without the use of specialized scores perfectly adequate? Some items used in the MASCC score (age, underlying disease, previous fungal infection, and initial outpatient status) are irrelevant for repeated assessment, and items such as "burden of illness," which are subjective and dependent on clinical experience, become key in assigning a low-risk or high-risk status. Obviously, following less formal institutional guidelines that allow for a great deal of clinical judgement, instead of using the MASCC score, may be adequate with respect to positive predictive value regarding rehospitalization rates [4, 28, 38, 39] , particularly if patients with new onset of febrile neutropenia are admitted to the hospital to receive an initial parenteral dose of empirical antibiotic therapy and remain hospitalized for some time under observation. The sensitivity of these approaches, however, is usually not known, but it is likely to be low.
Role of expected neutropenia duration. Some practicing oncologists and hematologists use the expected duration of neutropenia as a criterium to select a low-risk patient population for whom oral therapy and outpatient management might be considered. In fact, the observed duration of neutropenia correlates with the rate of response to initial therapy and ultimate outcomes. However, the likelihood of response to oral or parenteral therapy is similar when episodes are stratified according to different lengths of neutropenia duration ( figure  2) . Importantly, when a serious medical complication is used as an end point, the discriminatory power of the expected (rather than observed) prolonged duration of neutropenia at initial presentation was very moderate in the MASCC study [34] , and no other study has evaluated expected neutropenia duration as a predictive variable. Although it has been used in several prospective therapeutic clinical trials as exclusion criteria, investigators' expectation of prolonged neutropenia (17 days) was found to be unreliable [34] . Prediction rules based (retrospectively) on observed neutropenia [40] , among other variables, require prospective validation using expected neutropenia duration as a variable.
In a study from the United Kingdom, a surprisingly high concordance rate was observed between the MASCC scoring system and an institutional prediction rule using, among others, an anticipated duration of neutropenia of !7 days [28] . Another retrospective study among children proposed underlying disease (e.g., absence of acute myeloid leukemia, Burkitt, acute lymphoblastic leukemia induction, progressive/relapsed cancer with bone marrow involvement) as a useful surrogate marker for the variable anticipated neutropenia duration of !7 days to be included, together with acute comorbidity, in a model predicting a low risk of complications and/or microbiologically documented infections [41] . 
Figure 2.
Rates of success of oral and intravenous empirical therapy in subgroups of patients with different observed lengths of neutropenia, after fever onset, according to results from a randomized, controlled trial of patients with cancer, fever, and neutropenia. ITTA, intention-to-treat analysis; IV, intravenous; PO, oral; PPA, per-protocol analysis. Adapted from [26] .
Bacteremia or serious bacterial infection as an alternative end point. Some risk prediction models have used bacteremia or "serious" bacterial infection (in some cases also called "significant" or "invasive" infection) as an end point, instead of complications or adverse outcomes in general [42] [43] [44] [45] [46] [47] . Most of these studies are in the pediatric field. Some have been validated prospectively in the context of oral outpatient therapy. According to this approach, bacteremia or "serious" bacterial infection is used as a surrogate for a high risk of adverse outcomes. Using such a surrogate, instead of purely clinically defined end points, may have disadvantages. Bacteriuria, for example, has not been shown to be associated with an increased risk of adverse outcomes, compared with the risk associated with fever of unknown origin [48] . As discussed earlier, line infection due to coagulase-negative staphylococci may often require modified therapy, but it has not been linked to a high risk of severe complications, whereas bacteriologically undefined pneumonia is associated with a worse prognosis than are most other types of documented infection. Prognostically, different types of infection will be included in an end point such as "serious" bacterial infection, although they may require different consequences with respect to monitoring, therapy, and site of care. Of note is that sensitivities and negative predictive values calculated for the prediction of bacteremia (any organism) in pediatric patients with cancer were 190% in several published models, but specificities have been between 5% and 58% only, and the best positive predictive value was 33% [46] .
Investigators from South America have proposed and validated a simple prediction rule for pediatric patients with "invasive" bacterial infection as an end point that appears to perform well [45] . Independent risk variables identified included serum C-reactive protein levels 190 mg/L, hypotension, relapsed leukemia, thrombocytopenia (!50,000 platelets/mL), and recent (within 7 days) receipt of chemotherapy. The definition of "invasive" bacterial infection was a sort of composite end point and included bacteremia, positive results of bacterial culture of a specimen obtained from a usually sterile site (e.g., indwelling catheter, urine, or CSF), severe sepsis, or focal organ involvement in a child with hemodynamic instability and severe malaise. The prevalence of "invasive" bacterial infection, as defined for the purpose of the analysis, was 53% (low risk, 10%; no low risk, 82%). When this prediction rule was applied to a randomized controlled trial of outpatient versus inpatient treatment of low-risk patients, outcomes were similar. Thus, use of this algorithm appears to be safe for determining which patients are suitable for receipt of outpatient therapy, but it is also likely that the sensitivity of the rule can be increased, with respect to identifying patients who are at low risk for developing complications (rather than "invasive" bacterial infection) after discharge from the hospital.
Interestingly, the prevalence of types of infection with an unfavorable prognosis differs between patient populations that are defined by the MASCC score as being low-risk or not. Thus, there may be some concordance between models attempting to predict "serious" or "invasive" bacterial infection and the MASCC prediction rule (table 5) . In an observational study from South Africa [49] , bacteremia was observed in 36% of high-risk patients versus only 7% of low-risk patients, as defined by the MASCC score. Recently, similar preliminary data have been reported from a new MASCC survey [10] .
INFLAMMATORY MARKERS AND OTHER RAPID LABORATORY TESTS: FUTURE ADJUNCTS IN PREDICTION MODELS?
Bacteremia, particularly gram-negative bacteremia, may be associated with a high risk for complications and a lethal outcome, which is clearly higher than the risk for adverse outcomes associated with unexplained fever. There have been attempts to improve the prediction of bacteremia or gram-negative bacteremia by inflammatory markers measured in plasma or serum specimens, with or without additional clinical variables. In this respect, markers such as IL-6, IL-8, and procalcitonin appear to be more discriminative than C-reactive protein level [4, 50, 56] . Two studies found a high specificity for measuring the IL-8 level that virtually excluded the presence of gram-negative bacteremia if at fever onset the level was below a certain threshold value [51, 52] . At a cutoff of 0.5 ng/mL, procalcitonin levels can probably be used to predict the absence of bacteremia in general, with a high likelihood, with negative predictive values ranging between 84% and 94% [53] [54] [55] [56] [57] . Test results, however, depend on the time elapsed between the onset of fever and the time of blood sampling [58] . Also, some studies of the potential utility of procalcitonin values after stem-cell transplantation among patients with fever reported rather disappointing results [59, 60] . Inflammatory markers can also be used to predict clinical outcomes, rather than types of infection. Procalcitonin, for example, predicted failure of empirical therapy with a high negative-predictive value, which was similar to those achieved with the Talcott classification or the MASCC score [50] . In another study of patients with persisting fever, measurement of procalcitonin levels yielded a high negative predictive value for subsequent complications [61] . Measurement of the IL-8 level at onset of fever was shown to predict early clinical complications, with a sensitivity of 83% [62] . With reported high negative predictive values, selected markers could be useful for better identification of subgroups of patients at low risk for severe infection. Positive predictive values, however, are often only ∼50% or lower and have large confidence intervals, depending on the specific end point and type of marker, so that identification of high-risk subgroups presently appears to be difficult. It is conceivable that other rapid diagnostic tests, such as nucleic acid-based detection of the most common bloodstream pathogens, will be combined with inflammatory markers and clinical variables to yield improved risk prediction models for patients with febrile neutropenia.
CONCLUSIONS
There has been some progress in the development of rules that seek to predict a low risk of severe infection or clinical complications in patients with cancer, fever, and neutropenia, but prospective validation of sensitive prediction rules, such as the MASCC model, in a multicenter context among outpatients given oral antibiotics, is missing. Clinical judgement with consideration of comorbidities, general clinical characteristics, and performance status, remains critical in the risk-assessment process, and it is advisable to include a certain period of (inpatient) observation after completion of diagnostic evaluation and initiation of empirical therapy before a definitive site-of-care decision is made. Inflammatory markers, such as the procalcitonin level, currently have no role but are attractive and should be studied further in low-risk prediction models. Site-of-care decisions require thorough assessment not only of medical criteria, but also of psychosocial and organizational and/or logistic criteria. If there are no contraindications, oral antibiotic therapy can be initiated early. If the drug is well tolerated, there is no indication of severe infection and no significant comorbidity (according to short-term clinical follow up and incoming laboratory test results), the patient has consented, and there is time to ascertain the appropriate infrastructure to provide follow-up, the patient should be discharged from the hospital and given oral drug therapy. This practice appears to be an accepted treatment option, because of its likely advantages, which include reduced health care costs, less family disruption caused by prolonged and frequent hospitalizations, and an increased quality of life for patients.
